- Home
- BCTX vs IMNN Comparison
BCTX vs IMNN Comparison
Compare BCTX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- IMNN
- Stock Information
- Founded
- BCTX 2014
- IMNN 1982
- Country
- BCTX Canada
- IMNN United States
- Employees
- BCTX N/A
- IMNN N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- IMNN Health Care
- Exchange
- BCTX Nasdaq
- IMNN Nasdaq
- Market Cap
- BCTX 13.7M
- IMNN 12.1M
- IPO Year
- BCTX N/A
- IMNN 1985
- Fundamental
- Price
- BCTX $0.81
- IMNN $0.54
- Analyst Decision
- BCTX Strong Buy
- IMNN Buy
- Analyst Count
- BCTX 1
- IMNN 2
- Target Price
- BCTX $32.00
- IMNN $14.00
- AVG Volume (30 Days)
- BCTX 2.5M
- IMNN 3.8M
- Earning Date
- BCTX 06-16-2025
- IMNN 08-13-2025
- Dividend Yield
- BCTX N/A
- IMNN N/A
- EPS Growth
- BCTX N/A
- IMNN N/A
- EPS
- BCTX N/A
- IMNN N/A
- Revenue
- BCTX N/A
- IMNN N/A
- Revenue This Year
- BCTX N/A
- IMNN N/A
- Revenue Next Year
- BCTX N/A
- IMNN N/A
- P/E Ratio
- BCTX N/A
- IMNN N/A
- Revenue Growth
- BCTX N/A
- IMNN N/A
- 52 Week Low
- BCTX $0.69
- IMNN $0.37
- 52 Week High
- BCTX $29.40
- IMNN $3.65
- Technical
- Relative Strength Index (RSI)
- BCTX 14.56
- IMNN 41.60
- Support Level
- BCTX $0.69
- IMNN $0.48
- Resistance Level
- BCTX $3.00
- IMNN $0.80
- Average True Range (ATR)
- BCTX 0.20
- IMNN 0.08
- MACD
- BCTX -0.15
- IMNN 0.01
- Stochastic Oscillator
- BCTX 4.75
- IMNN 42.24
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).